UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 orOR 15(d) of The Securities Exchange Act of 1934

Date of ~~the~~Report ~~Securities~~(Date ~~Exchange~~of ~~Act~~earliest ofevent ~~1934~~reported): August 13, 2025

Date of Report (Date of earliest event reported): May 28, 2025

INHIBRX BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-42031

99-0613523

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(IRS Employer
Identification No.)

11025 N. Torrey Pines Road, Suite 140

La Jolla, CA 92037

(Address of Principal Executive Offices and Zip Code)

Registrant’s telephone number, including area code: (858) 795-4220

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	INBX	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 5 2.~~07 Submission~~02 Results of ~~Matters~~Operations toand aFinancial ~~Vote of Security Holders~~Condition

~~The~~On August 13, 2025, ~~Annual Meeting of Stockholders (the “Annual Meeting”) of~~ Inhibrx Biosciences, Inc. (the “Company”) ~~was~~issued ~~held on May 28, 2025 at 10:00~~ a~~.m.~~ ~~Pacific~~press ~~Time~~release ~~online~~announcing inits afinancial ~~virtual~~results ~~format. Of~~for the ~~Company’s~~three ~~14,475,904 shares of common stock issued~~ and ~~outstanding~~six ~~and~~months ~~eligible~~ended toJune ~~vote as of the record date of April 1~~30, 2025,. aA ~~quorum~~copy of ~~11,493,284 shares, or approximately 79% of~~ the ~~eligible~~press ~~shares,~~release ~~was present virtually or represented by proxy. Each of the matters set forth below~~ is ~~described~~furnished inas ~~detail~~Exhibit ~~in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 16, 2025~~99.1 ~~The~~to ~~following~~this ~~actions were taken at the Annual Meeting:~~report.

~~Proposal~~The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

~~Election~~Item 9.01. Financial ofStatements ~~the following nominees as Class I Directors of the Company, each to serve until the 2028 Annual Meeting~~ and ~~until their respective successor is duly elected and qualified~~Exhibits.

	Votes For	Votes Withheld	Broker Non-Votes
Jon Faiz Kayyem, Ph.D.	8,077,611	31,060	3,384,613
Kristiina Vuori, M.D., Ph.D.	6,494,317	1,614,354	3,384,613

(d) Exhibits.

Proposal 2


Exhibit No.						Description
99.1						Press Release issued by Inhibrx Biosciences, Inc. on August 13 , 2025

104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

Ratification of the selection of BDO USA, P.C. as the Company’s independent registered public accounting firm for the year ending December 31, 2025.

Votes For			Votes Against			Votes Abstained			Broker Non-Votes
11,463,328			2,918			27,038			0

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 28, 2025
Date: August 13, 2025
	INHIBRX BIOSCIENCES, INC.
	By:	/s/ ~~Leah~~Kelly ~~Pollema~~Deck
	Name:	~~Leah~~Kelly ~~Pollema~~Deck
	Title:	~~VP,~~Chief ~~General~~Financial ~~Counsel and Corporate Secretary~~Officer

Filing Compare · Inhibrx Biosciences, Inc.